These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22802555)

  • 1. Exacerbation of AIH in a patient with an AIH/systemic sclerosis overlap syndrome and pulmonary arterial hypertension treated with the endothelin-1 receptor antagonist sitaxentan.
    Klein R; Hintz E; Staehler G
    BMJ Case Rep; 2012 Jul; 2012():. PubMed ID: 22802555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension.
    Lee WT; Kirkham N; Johnson MK; Lordan JL; Fisher AJ; Peacock AJ
    Eur Respir J; 2011 Feb; 37(2):472-4. PubMed ID: 21282815
    [No Abstract]   [Full Text] [Related]  

  • 3. [Autoimmune hepatitis and overlap syndrome: diagnosis].
    Berg PA; Klein R
    Praxis (Bern 1994); 2002 Aug; 91(34):1339-46. PubMed ID: 12233264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver toxicity of sitaxentan in pulmonary arterial hypertension.
    Galiè N; Hoeper MM; Simon J; Gibbs R; Simonneau G;
    Eur Heart J; 2011 Feb; 32(4):386-7. PubMed ID: 21416695
    [No Abstract]   [Full Text] [Related]  

  • 5. Sitaxentan: in pulmonary arterial hypertension.
    Scott LJ
    Drugs; 2007; 67(5):761-70; discussion 771-2. PubMed ID: 17385944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver toxicity of sitaxentan in pulmonary arterial hypertension.
    Galiè N; Hoeper MM; Gibbs JS; Simonneau G
    Eur Respir J; 2011 Feb; 37(2):475-6. PubMed ID: 21282816
    [No Abstract]   [Full Text] [Related]  

  • 7. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis.
    Becker MO; Kill A; Kutsche M; Guenther J; Rose A; Tabeling C; Witzenrath M; Kühl AA; Heidecke H; Ghofrani HA; Tiede H; Schermuly RT; Nickel N; Hoeper MM; Lukitsch I; Gollasch M; Kuebler WM; Bock S; Burmester GR; Dragun D; Riemekasten G
    Am J Respir Crit Care Med; 2014 Oct; 190(7):808-17. PubMed ID: 25181620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.
    Safdar Z
    Vasc Health Risk Manag; 2011; 7():119-24. PubMed ID: 21468170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
    Shetty N; Derk CT
    Inflamm Allergy Drug Targets; 2011 Feb; 10(1):19-26. PubMed ID: 21184655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The significance of anti-soluble liver antigen/liver-pancreas in diagnosing and typing autoimmune hepatitis].
    Zhao Y; Yan HP; Tan YF; Feng X; Liu Y; Cui D; Ma DM; Li WH; Zhang HP
    Zhonghua Gan Zang Bing Za Zhi; 2007 Apr; 15(4):283-6. PubMed ID: 17456317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P; Coghlan G
    Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies and autoantigens in autoimmune hepatitis.
    Strassburg CP; Manns MP
    Semin Liver Dis; 2002 Nov; 22(4):339-52. PubMed ID: 12447706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension.
    Lavelle A; Sugrue R; Lawler G; Mulligan N; Kelleher B; Murphy DM; Gaine SP
    Eur Respir J; 2009 Sep; 34(3):770-1. PubMed ID: 19720812
    [No Abstract]   [Full Text] [Related]  

  • 14. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension.
    Iannone F; Riccardi MT; Guiducci S; Bizzoca R; Cinelli M; Matucci-Cerinic M; Lapadula G
    Ann Rheum Dis; 2008 Aug; 67(8):1121-6. PubMed ID: 18029384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.
    Horn EM; Widlitz AC; Barst RJ
    Expert Opin Investig Drugs; 2004 Nov; 13(11):1483-92. PubMed ID: 15500395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.
    O'Callaghan DS; Gaine SP
    Int J Clin Pract; 2006 Apr; 60(4):475-81. PubMed ID: 16620363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune hepatitis in children: what is different from adult AIH?
    Mieli-Vergani G; Vergani D
    Semin Liver Dis; 2009 Aug; 29(3):297-306. PubMed ID: 19676002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitaxentan: new drug. Pulmonary hypertension: better to continue to use bosentan.
    Prescrire Int; 2008 Jun; 17(95):108. PubMed ID: 18630348
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan.
    Kähler CM; Graziadei I; Vogelsinger H; Desole S; Cima K; Vogel W
    Wien Klin Wochenschr; 2011 Apr; 123(7-8):248-52. PubMed ID: 21451953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antibodies and physiopathogeny of autoimmune hepatitis].
    García-Leiva J; Ríos-Vaca A; Torre-Delgadillo A
    Rev Invest Clin; 2003; 55(5):577-82. PubMed ID: 14968479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.